Search Results

Valve Medical’s Xemed TAVR System Used in First-in-Human Implantation in Israel

May 31, 2023—Valve Medical, a wholly owned subsidiary of Medinol Ltd., announced the successful first-in-human implantation of the company’s Xemed transcatheter aortic valve replacement (TAVR) system, which features a modular valve.

CE Mark Approval for InSeal Medical's Large-Bore InClosure VCD

August 8, 2016—InSeal Medical Ltd. (Caesarea, Israel) announced that it has received CE Mark approval for its dedicated large-bore vascular closure device (VCD).

Filterlex’s Captis Embolic Protection Device Evaluated With TAVR in FIH Study

May 31, 2022—Filterlex Medical Ltd., an Israel-based cardiovascular medical device startup, announced results from a first-in-human (FIH) study demonstrating the safety, feasibility, and performance of the Captis embolic protection device.

Filterlex Medical Completes Funding Round for Its Captis Clinical Program

November 18, 2021—Filterlex Medical Ltd., a cardiovascular medical device startup company based in Israel, announced that it has recently completed a $6 million Series A1 investment round from leading private health care investors.

Valve-in-Valve Procedures With Medtronic's CoreValve Approved in Europe

May 23, 2013—Medtronic, Inc. (Minneapolis, MN) announced it has received CE Mark approval for valve-in-valve (VIV) procedures using the CoreValve and CoreValve Evolut transcatheter aortic valve replacement (TAVR) systems in degenerated bioprosthetic surgical aortic valves.

Trisol Begins Early Feasibility Study of Transcatheter Tricuspid Valve in the United States

August 29, 2023—Trisol Medical Ltd., which is based in Yokneam, Israel, recently announced the first two implantations in the United States of the Trisol transcatheter tricuspid valve replacement device as part of an FDA-approved early feasibility study (EFS), which is led by Principal Investigator Isaac George, MD.

Two Studies Support Staged PCI for Multivessel Disease in STEMI Patients

August 9, 2011—In the Journal of the American College of Cardiology, Pieter J. Vlaar, MD, et al published findings from a study that sought to investigate whether, in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease (MVD), percutaneous coronary intervention (PCI) should be confined to the culprit vessel or also include nonculprit vessels and, when performing PCI for nonculprit vessels, whether it should take place during primary PCI or staged procedures (2011;58:692–703). The background of the study is that a significant percentage of STEMI patients have MVD. However, the best PCI strategy for nonculprit vessel lesions is unknown, the investigators noted.

Medtronic's Resolute Integrity DES Approved for New Indications in Europe

May 15, 2012—At the EuroPCR 2012 conference in Paris, Medtronic, Inc. (Minneapolis, MN) announced that the Resolute Integrity coronary drug-eluting stent (DES) system has received European regulatory approval for several new indications: acute coronary syndrome, acute myocardial infarction, unstable angina, total occlusions and chronic total occlusions, and in-stent restenosis.